Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V116 in adults living with HIV
NCT05393037Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A, Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part A and 2 more. Started Jul 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05393037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393037.